A comparison of gene expression profiling tests for breast cancer
Smartt P
Record ID 32010001703
English
Authors' recommendations:
Overall, the additional studies addressed some, but not all, of the outstanding issues relating to the evidence of the clinical validity and clinical utility of these tests in patients with breast cancer. The largest volume of evidence related to the Oncotype DX™ test. Very few of these studies in isolation provided compelling evidence of the clinical utility of gene profiling test and the overall the quality (and therefore the strength of the evidence they provided) of most of the studies was low. The results of the two ongoing RCTs, MINDACT and TAILORx, which aim to provide almost direct evidence for Oncotype DX™, and for MammaPrint®, remain the most likely source of clinical proof of the utility of these tests.
Details
Project Status:
Completed
URL for project:
http://www.healthsac.net/downloads/publications/HSAC31%20Gene%20Expression%20Profiling%20070710%20FINAL.pdf
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
New Zealand
MeSH Terms
- Breast Neoplasms
Contact
Organisation Name:
Health Services Assessment Collaboration
Contact Address:
University of Canterbury, Private Bag 4800, Christchurch 8140, New Zealand
Contact Name:
hsac@canterbury.ac.nz
Contact Email:
hsac@canterbury.ac.nz
Copyright:
Health Services Assessment Collaboration (HSAC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.